VP of Business Development and Licensing
Opportunity to define BD at a category-defining AI biologics company. Clear path to Chief Business Officer. High ownership, direct CEO exposure, and meaningful impact on company trajectory.
We usually respond within a day
Antiverse
Engineering the future of antibody drug development to change the course of people’s lives!
Do you want to be part of an ambitious techbio start-up successfully tackling an issue nobody thought possible?
We are seeking a VP of Business Development & Licensing to build and expand Antiverse’s portfolio of strategic partnerships, with a focus on securing high-value collaborations with global pharma.
This role will be responsible for shaping and executing Antiverse’s business development strategy, while building the foundations of a world-class BD function, with a clear path to Chief Business Officer.
Join us to grow and evolve with a company transforming drug discovery!
Culture and Values
We believe in the power of autonomy nurtured in a culture with the following values.
People first
We work to make things better for everyone: both on a societal level and a personal level. We will thrive, as a team, as a company and as a society by combining smartness with thoughtfulness across everything we do.
Rigour & agility
We move fast and innovate in our thinking, yet combine this agility with utter rigour and robustness. We are dedicated to delivering rock-solid solutions.
Interdisciplinarity
Our interdisciplinary approach goes deeper than our science. We believe that the best ideas and the most interesting conversations often come from synthesising diverse expertise and experiences.
Dignity & nurture
We fundamentally believe in the value of each individual and the worth of their contribution regardless of the outcome. We believe that we all thrive best in a nurturing environment, and everything in our power is committed to building this supportive culture.
Go where there's a need
We have the potential to transform lives. We will not let ourselves be sidetracked in this calling. We will not fail those whose future we can save.
Role
This role will be responsible for shaping and executing Antiverse’s business development strategy, while building the foundations of a world-class BD function, with a clear path to Chief Business Officer.
Own a focused set of high-priority pharma accounts
Lead deals from initial engagement through to signed agreement
Structure and negotiate complex licensing and collaboration agreements
Transition Antiverse to targeted, account-driven BD
Build deep, multi-threaded relationships with senior decision-makers (SVP+, CSO, BD leadership)
Position Antiverse as a long-term strategic partner
Partner with the C-suite and board on partnership strategy and positioning
Translate platform and pipeline capabilities into compelling deal narratives
Optimise deal structures across upfronts, milestones, and multi-target frameworks
Establish BD processes, CRM discipline, and account planning frameworks
Hire and develop a high-performing BD team over time
Collaborate closely with marketing, scientific leadership, and external partners
Significant experience in biotech/pharma BD&L
Demonstrated track record of closing strategic partnerships
Experience with platform companies (AI drug discovery, biologics, GPCRs or related areas is a plus)
Strategic thinker with strong execution capability
Comfortable operating in a fast-moving, early-stage environment
Benefits
Competitive base salary - DOE
Stock Options
25 days + public holidays
3 Summer Fridays
Private medical insurance
Flexible working hours
Office in Kendall Square
Allowances for equipment, both for home and office
Discounted Gym and Pool membership
Referral Bonus
No recruiters, please.
- Department
- Discovery Team
- Locations
- Boston
- Remote status
- Hybrid
About Antiverse
Antiverse was founded by Ben Holland, Murat Tunaboylu and Rowina Westermeir at the Deep Science Ventures Accelerator Programme in 2017. Their objective was to create new enabling technologies in antibody discovery using artificial intelligence that allows for the creation of new therapies against the industry's most challenging targets. Since then, Antiverse has worked with five companies in antibody discovery programmes aimed at several GPCRs, Ion Channels and other challenging targets. In addition, we are developing our own internal pipeline, and have raised around $10.1 million.